Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 6/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL106826 | 1.00 | GLO1 (0.50) | GLO1KMT2AMEN1PAX8LMNA | |
| Dimethyl Sulfoxide SCHEMBL138731 | 0.94 | GLO1 (0.48) | GLO1KMT2AMEN1PAX8LMNA | |
| SCHEMBL28279585 | 0.92 | GLO1 (0.46) | GLO1KMT2AMEN1PAX8LMNA | |
| SCHEMBL4450762 | 0.77 | KMT2A (0.57) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL4450765 | 0.77 | KMT2A (0.57) | KMT2AMEN1LMNAALDH1A1KDM4E | |
| SCHEMBL9341971 | 0.75 | CES2 (0.44) | KMT2AMEN1ALDH1A1KDM4ETDP1 | |
| SCHEMBL29754411 | 0.74 | GLO1 (0.41) | GLO1KMT2AMEN1PAX8LMNA | |
| SCHEMBL30306284 | 0.73 | RAB9A (0.44) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL23928456 | 0.72 | MITF (0.65) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL23928455 | 0.72 | MITF (0.65) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222066-A1 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2025-07-10 | — | — | US | claimed |
| EP-4547023-A2 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | University of Utah Research Foundation (US) | 2025-05-07 | — | — | EP | claimed |
| US-20240271119-A1 | METHODS OF PERIPLASMIC PHAGE-ASSISTED CONTINUOUS EVOLUTION | THE BROAD INSTITUTE, INC. (US) | 2024-08-15 | — | — | US | claimed |
| EP-4377455-A1 | METHODS OF PERIPLASMIC PHAGE-ASSISTED CONTINUOUS EVOLUTION | The Broad Institute Inc. (US) | 2024-06-05 | — | — | EP | claimed |
| WO-2024085926-A2 | COMPOSITIONS AND METHODS OF TREATING, PREVENTING OR INHIBITING A FACULTATIVE ANAEROBE INFECTION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2023010050-A1 | METHODS OF PERIPLASMIC PHAGE-ASSISTED CONTINUOUS EVOLUTION | THE BROAD INSTITUTE, INC. (US) | 2023-02-02 | — | — | WO | claimed |
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2022-07-14 | — | — | US | claimed |
| EP-3199630-B1 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | HARVARD COLLEGE (US) | 2019-05-08 | — | — | EP | claimed |
| US-9771574-B2 | Apparatus for continuous directed evolution of proteins and nucleic acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-09-26 | — | — | US | claimed |
| EP-3199630-A1 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | President and Fellows of Harvard College (US) | 2017-08-02 | — | — | EP | claimed |
| EP-2655614-A2 | CONTINUOUS DIRECTED EVOLUTION | President and Fellows of Harvard College (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012088381-A2 | CONTINUOUS DIRECTED EVOLUTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-06-28 | — | — | WO | claimed |
| US-20110177495-A1 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-07-21 | — | — | US | claimed |
| EP-2342336-A2 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | President and Fellows of Harvard College (US) | 2011-07-13 | — | — | EP | claimed |
| US-20110118127-A1 | MARKER GENES FOR SCREENING OF DRUG-INDUCED TOXICITY IN HUMAN CELLS AND SCREENING METHOD USING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-19 | — | — | US | claimed |
| WO-2010028347-A2 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2010-03-11 | — | — | WO | claimed |
| US-7539006-B2 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2009-05-26 | — | — | US | claimed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218639-A1 | TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS | PLAT, PLG, PLAUR | GLO1 2542/4885KMT2A 3870/4885MEN1 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.